{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package omw-1.4 to\n",
      "[nltk_data]     C:\\Users\\ariesenihw\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package omw-1.4 is already up-to-date!\n",
      "[nltk_data] Downloading package punkt to\n",
      "[nltk_data]     C:\\Users\\ariesenihw\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n",
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     C:\\Users\\ariesenihw\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n",
      "[nltk_data] Downloading package wordnet to\n",
      "[nltk_data]     C:\\Users\\ariesenihw\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package wordnet is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import statsmodels.formula.api as sm\n",
    "\n",
    "import nltk\n",
    "nltk.download('omw-1.4')\n",
    "nltk.download('punkt')  # Download the Punkt tokenizer if you haven't already\n",
    "\n",
    "from nltk.tokenize import sent_tokenize\n",
    "\n",
    "import re\n",
    "from string import punctuation\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "from nltk.corpus import stopwords\n",
    "import nltk\n",
    "nltk.download('stopwords')\n",
    "nltk.download('wordnet')\n",
    "from PIL import Image\n",
    "\n",
    "\n",
    "# Plot settings\n",
    "plt.rcParams['figure.figsize'] = (12, 9)\n",
    "plt.rcParams['font.size'] = 12"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Alright let's review the scraped data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PubMedID</th>\n",
       "      <th>Title</th>\n",
       "      <th>URL</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>37899090</td>\n",
       "      <td>Therapy with direct oral anticoagulants for se...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37899090</td>\n",
       "      <td>Antiphospholipid syndrome (APS) is a systemic ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>37878348</td>\n",
       "      <td>Treatment Outcomes With Licensed and Unlicense...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37878348</td>\n",
       "      <td>Stimulants (methylphenidate and amphetamines) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>37866803</td>\n",
       "      <td>AdipoRon and ADP355, adiponectin receptor agon...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37866803</td>\n",
       "      <td>Adiponectin replacement therapy holds the pote...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>37864589</td>\n",
       "      <td>Exploring the logic and conducting a comprehen...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37864589</td>\n",
       "      <td>The potential benefits of adiponectin replacem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>37846549</td>\n",
       "      <td>Evaluation of pentamidine tolerability and eff...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37846549</td>\n",
       "      <td>Intravenous pentamidine is used for prophylaxi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5832</th>\n",
       "      <td>1964663</td>\n",
       "      <td>Therapeutic application of subcutaneous low-mo...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/1964663</td>\n",
       "      <td>Fifty patients presenting with acute deep-vein...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5833</th>\n",
       "      <td>2563187</td>\n",
       "      <td>Relative efficacy of, and some adverse reactio...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/2563187</td>\n",
       "      <td>Although it is a common belief that all antihy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5834</th>\n",
       "      <td>3124679</td>\n",
       "      <td>Advanced ovarian cancer: long-term results of ...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/3124679</td>\n",
       "      <td>To determine the efficacy of a 6-month course ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5835</th>\n",
       "      <td>3431880</td>\n",
       "      <td>The analgesic effect of amitriptyline on chron...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/3431880</td>\n",
       "      <td>The efficacy of amitriptyline was evaluated in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5836</th>\n",
       "      <td>2444780</td>\n",
       "      <td>Comparison of nitroglycerin patches and nifedi...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/2444780</td>\n",
       "      <td>Fifteen patients with stable angina participat...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5837 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      PubMedID                                              Title  \\\n",
       "0     37899090  Therapy with direct oral anticoagulants for se...   \n",
       "1     37878348  Treatment Outcomes With Licensed and Unlicense...   \n",
       "2     37866803  AdipoRon and ADP355, adiponectin receptor agon...   \n",
       "3     37864589  Exploring the logic and conducting a comprehen...   \n",
       "4     37846549  Evaluation of pentamidine tolerability and eff...   \n",
       "...        ...                                                ...   \n",
       "5832   1964663  Therapeutic application of subcutaneous low-mo...   \n",
       "5833   2563187  Relative efficacy of, and some adverse reactio...   \n",
       "5834   3124679  Advanced ovarian cancer: long-term results of ...   \n",
       "5835   3431880  The analgesic effect of amitriptyline on chron...   \n",
       "5836   2444780  Comparison of nitroglycerin patches and nifedi...   \n",
       "\n",
       "                                           URL  \\\n",
       "0     https://pubmed.ncbi.nlm.nih.gov/37899090   \n",
       "1     https://pubmed.ncbi.nlm.nih.gov/37878348   \n",
       "2     https://pubmed.ncbi.nlm.nih.gov/37866803   \n",
       "3     https://pubmed.ncbi.nlm.nih.gov/37864589   \n",
       "4     https://pubmed.ncbi.nlm.nih.gov/37846549   \n",
       "...                                        ...   \n",
       "5832   https://pubmed.ncbi.nlm.nih.gov/1964663   \n",
       "5833   https://pubmed.ncbi.nlm.nih.gov/2563187   \n",
       "5834   https://pubmed.ncbi.nlm.nih.gov/3124679   \n",
       "5835   https://pubmed.ncbi.nlm.nih.gov/3431880   \n",
       "5836   https://pubmed.ncbi.nlm.nih.gov/2444780   \n",
       "\n",
       "                                               Abstract  \n",
       "0     Antiphospholipid syndrome (APS) is a systemic ...  \n",
       "1     Stimulants (methylphenidate and amphetamines) ...  \n",
       "2     Adiponectin replacement therapy holds the pote...  \n",
       "3     The potential benefits of adiponectin replacem...  \n",
       "4     Intravenous pentamidine is used for prophylaxi...  \n",
       "...                                                 ...  \n",
       "5832  Fifty patients presenting with acute deep-vein...  \n",
       "5833  Although it is a common belief that all antihy...  \n",
       "5834  To determine the efficacy of a 6-month course ...  \n",
       "5835  The efficacy of amitriptyline was evaluated in...  \n",
       "5836  Fifteen patients with stable angina participat...  \n",
       "\n",
       "[5837 rows x 4 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = pd.read_csv(\"pubmed_data_full.csv\")\n",
    "data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's check if we have null values."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "PubMedID      0\n",
       "Title         0\n",
       "URL           0\n",
       "Abstract    256\n",
       "dtype: int64"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.isnull().sum()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Alright we see 256 entries have NaN for the abstract so let's drop these."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PubMedID</th>\n",
       "      <th>Title</th>\n",
       "      <th>URL</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>37899090</td>\n",
       "      <td>Therapy with direct oral anticoagulants for se...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37899090</td>\n",
       "      <td>Antiphospholipid syndrome (APS) is a systemic ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>37878348</td>\n",
       "      <td>Treatment Outcomes With Licensed and Unlicense...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37878348</td>\n",
       "      <td>Stimulants (methylphenidate and amphetamines) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>37866803</td>\n",
       "      <td>AdipoRon and ADP355, adiponectin receptor agon...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37866803</td>\n",
       "      <td>Adiponectin replacement therapy holds the pote...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>37864589</td>\n",
       "      <td>Exploring the logic and conducting a comprehen...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37864589</td>\n",
       "      <td>The potential benefits of adiponectin replacem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>37846549</td>\n",
       "      <td>Evaluation of pentamidine tolerability and eff...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/37846549</td>\n",
       "      <td>Intravenous pentamidine is used for prophylaxi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5832</th>\n",
       "      <td>1964663</td>\n",
       "      <td>Therapeutic application of subcutaneous low-mo...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/1964663</td>\n",
       "      <td>Fifty patients presenting with acute deep-vein...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5833</th>\n",
       "      <td>2563187</td>\n",
       "      <td>Relative efficacy of, and some adverse reactio...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/2563187</td>\n",
       "      <td>Although it is a common belief that all antihy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5834</th>\n",
       "      <td>3124679</td>\n",
       "      <td>Advanced ovarian cancer: long-term results of ...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/3124679</td>\n",
       "      <td>To determine the efficacy of a 6-month course ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5835</th>\n",
       "      <td>3431880</td>\n",
       "      <td>The analgesic effect of amitriptyline on chron...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/3431880</td>\n",
       "      <td>The efficacy of amitriptyline was evaluated in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5836</th>\n",
       "      <td>2444780</td>\n",
       "      <td>Comparison of nitroglycerin patches and nifedi...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/2444780</td>\n",
       "      <td>Fifteen patients with stable angina participat...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5581 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      PubMedID                                              Title  \\\n",
       "0     37899090  Therapy with direct oral anticoagulants for se...   \n",
       "1     37878348  Treatment Outcomes With Licensed and Unlicense...   \n",
       "2     37866803  AdipoRon and ADP355, adiponectin receptor agon...   \n",
       "3     37864589  Exploring the logic and conducting a comprehen...   \n",
       "4     37846549  Evaluation of pentamidine tolerability and eff...   \n",
       "...        ...                                                ...   \n",
       "5832   1964663  Therapeutic application of subcutaneous low-mo...   \n",
       "5833   2563187  Relative efficacy of, and some adverse reactio...   \n",
       "5834   3124679  Advanced ovarian cancer: long-term results of ...   \n",
       "5835   3431880  The analgesic effect of amitriptyline on chron...   \n",
       "5836   2444780  Comparison of nitroglycerin patches and nifedi...   \n",
       "\n",
       "                                           URL  \\\n",
       "0     https://pubmed.ncbi.nlm.nih.gov/37899090   \n",
       "1     https://pubmed.ncbi.nlm.nih.gov/37878348   \n",
       "2     https://pubmed.ncbi.nlm.nih.gov/37866803   \n",
       "3     https://pubmed.ncbi.nlm.nih.gov/37864589   \n",
       "4     https://pubmed.ncbi.nlm.nih.gov/37846549   \n",
       "...                                        ...   \n",
       "5832   https://pubmed.ncbi.nlm.nih.gov/1964663   \n",
       "5833   https://pubmed.ncbi.nlm.nih.gov/2563187   \n",
       "5834   https://pubmed.ncbi.nlm.nih.gov/3124679   \n",
       "5835   https://pubmed.ncbi.nlm.nih.gov/3431880   \n",
       "5836   https://pubmed.ncbi.nlm.nih.gov/2444780   \n",
       "\n",
       "                                               Abstract  \n",
       "0     Antiphospholipid syndrome (APS) is a systemic ...  \n",
       "1     Stimulants (methylphenidate and amphetamines) ...  \n",
       "2     Adiponectin replacement therapy holds the pote...  \n",
       "3     The potential benefits of adiponectin replacem...  \n",
       "4     Intravenous pentamidine is used for prophylaxi...  \n",
       "...                                                 ...  \n",
       "5832  Fifty patients presenting with acute deep-vein...  \n",
       "5833  Although it is a common belief that all antihy...  \n",
       "5834  To determine the efficacy of a 6-month course ...  \n",
       "5835  The efficacy of amitriptyline was evaluated in...  \n",
       "5836  Fifteen patients with stable angina participat...  \n",
       "\n",
       "[5581 rows x 4 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.dropna(inplace=True)\n",
    "data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "And let's see if the scraper didn't take any duplicates."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count                                                  5581\n",
       "unique                                                 5579\n",
       "top       We identified 16 randomized placebo-controlled...\n",
       "freq                                                      2\n",
       "Name: Abstract, dtype: object"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data['Abstract'].describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "two duplicates let's look at those\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PubMedID</th>\n",
       "      <th>Title</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Abstract</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>The optimal strategy for revascularization in infrainguinal chronic limb-threatening ischemia (CLTI) remains debatable. Comparative trials are scarce, and daily decisions are often made using anecdotal or low-quality evidence. We searched multiple databases through May 7, 2017, for prospective studies with at least 1-year follow-up that evaluated patient-relevant outcomes of infrainguinal revascularization procedures in adults with CLTI. Independent pairs of reviewers selected articles and extracted data. Random-effects meta-analysis was used to pool outcomes across studies. We included 44 studies that enrolled 8602 patients. Periprocedural outcomes (mortality, amputation, major adverse cardiac events) were similar across treatment modalities. Overall, patients with infrapopliteal disease had higher patency rates of great saphenous vein graft at 1 and 2Â years (primary: 87%, 78%; secondary: 94%, 87%, respectively) compared with all other interventions. Prosthetic bypass outcomes were notably inferior to vein bypass in terms of amputation and patency outcomes, especially for below knee targets at 2Â years and beyond. Drug-eluting stents demonstrated improved patency over bare-metal stents in infrapopliteal arteries (primary patency: 73% vs 50% at 1Â year), and was at least comparable to balloon angioplasty (66% primary patency). Survival, major amputation, and amputation-free survival at 2Â years were broadly similar between endovascular interventions and vein bypass, with prosthetic bypass having higher rates of limb loss. Overall, the included studies were at moderate to high risk of bias and the quality of evidence was low. There are major limitations in the current state of evidence guiding treatment decisions in CLTI, particularly for severe anatomic patterns of disease treated via endovascular means. Periprocedural (30-day) mortality, amputation, and major adverse cardiac events are broadly similar across modalities. Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets. Among endovascular interventions, percutaneous transluminal angioplasty and drug-eluting stents appear comparable for focal infrapopliteal disease, although no studies included long segment tibial lesions. Heterogeneity in patient risk, severity of limb threat, and anatomy treated renders direct comparison of outcomes from the current literature challenging. Future studies should incorporate both limb severity and anatomic staging to best guide clinical decision making in CLTI.</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                    PubMedID  Title  URL\n",
       "Abstract                                                                \n",
       "The optimal strategy for revascularization in i...         2      2    2\n",
       "We identified 16 randomized placebo-controlled ...         2      2    2"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duplicates = data.groupby('Abstract').count()\n",
    "mask = duplicates['PubMedID'] >= 2\n",
    "duplicates[mask]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count                                                  5579\n",
       "unique                                                 5579\n",
       "top       Antiphospholipid syndrome (APS) is a systemic ...\n",
       "freq                                                      1\n",
       "Name: Abstract, dtype: object"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data['Abstract'] = data['Abstract'].str.strip()\n",
    "data = data.drop_duplicates(subset='Abstract')\n",
    "data['Abstract'].describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now all duplicates and rows with NaN values have been removed"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's inspect the top 30 most common words in the abstracts."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x900 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "word_freq = {}\n",
    "for sentence in data[\"Abstract\"]:\n",
    "    words = sentence.split()\n",
    "    for word in words:\n",
    "        if word not in word_freq:\n",
    "            word_freq[word] = 1\n",
    "        else: word_freq[word] += 1\n",
    "\n",
    "df_word_freq = pd.DataFrame.from_dict(word_freq, orient='index', columns=['Frequency'])\n",
    "df_word_freq = df_word_freq.sort_values(by='Frequency', ascending=False)\n",
    "\n",
    "# Plot the word frequencies using seaborn\n",
    "sns.barplot(x=df_word_freq.index[:30], y=df_word_freq['Frequency'][:30])\n",
    "plt.xticks(rotation=90)\n",
    "plt.xlabel('Words')\n",
    "plt.ylabel('Frequency')\n",
    "plt.title('Top 30 Word Frequencies')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "As we see stopwords take up most of the spots in the 30 most recurring words. Let's remove these to paint a better picture of the 30 most common words in my corpus excluding stopwords."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_text(text):\n",
    "    if type(text) != str or text=='':\n",
    "        return ''\n",
    "\n",
    "    text = text.lower()\n",
    "    text = re.sub(r\"<.*?>\", \" \", text)\n",
    "    text = re.sub(r\"(?<=\\b\\w) n't\", \" not\", text)\n",
    "    text = re.sub(\"\\'ll\", \" will\", text)\n",
    "    text = re.sub(\"what\\'s \", \" what is \", text, flags=re.IGNORECASE)\n",
    "    text = re.sub(\"&\", \"and\", text)\n",
    "    text = re.sub(\"\\'ve\", \" have \", text)\n",
    "    text = re.sub(r'i\\'m', 'i am', text)\n",
    "    #remove stopwords and apply lemmatization instead of stemming because it is more accurate in most cases.\n",
    "    stopwords_set = set(stopwords.words('english'))\n",
    "    lemmatizer = WordNetLemmatizer()\n",
    "    text = text.split()\n",
    "    text = [word for word in text if word.lower() not in stopwords_set]\n",
    "    text = [lemmatizer.lemmatize(word) for word in text]\n",
    "    \n",
    "    return \" \".join(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "179\n"
     ]
    }
   ],
   "source": [
    "stopwords_set = set(stopwords.words('english'))\n",
    "print(len(stopwords_set))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x900 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "cleaned_data = data['Abstract'].apply(clean_text)\n",
    "word_freq = {}\n",
    "for sentence in cleaned_data:\n",
    "    words = sentence.split()\n",
    "    for word in words:\n",
    "        if word not in word_freq:\n",
    "            word_freq[word] = 1\n",
    "        else: word_freq[word] += 1\n",
    "\n",
    "df_word_freq = pd.DataFrame.from_dict(word_freq, orient='index', columns=['Frequency'])\n",
    "df_word_freq = df_word_freq.sort_values(by='Frequency', ascending=False)\n",
    "\n",
    "# Plot the word frequencies using seaborn\n",
    "sns.barplot(x=df_word_freq.index[:30], y=df_word_freq['Frequency'][:30])\n",
    "plt.xticks(rotation=90)\n",
    "plt.xlabel('Words')\n",
    "plt.ylabel('Frequency')\n",
    "plt.title('Top 30 Word Frequencies')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Here we see now that more words we would expect from a corpus based on drug trials and mechanisms of action can be seen in the top 30 let's make a wordcloud to see these distribution in a different way. to see if we can spot other important themes in our data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Only supported for TrueType fonts",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[1;32mC:\\Users\\ARIESE~1\\AppData\\Local\\Temp/ipykernel_21816/1376120410.py\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[0mtotal_text\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;34m\" \"\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mabstract\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mabstract\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mdata\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m'Abstract'\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      5\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 6\u001b[1;33m \u001b[0mword_cloud\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mWordCloud\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtotal_text\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m      7\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      8\u001b[0m \u001b[0mplt\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mimshow\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mword_cloud\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0minterpolation\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m'bilinear'\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate\u001b[1;34m(self, text)\u001b[0m\n\u001b[0;32m    637\u001b[0m         \u001b[0mself\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    638\u001b[0m         \"\"\"\n\u001b[1;32m--> 639\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate_from_text\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtext\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    640\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    641\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m_check_generated\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_text\u001b[1;34m(self, text)\u001b[0m\n\u001b[0;32m    619\u001b[0m         \"\"\"\n\u001b[0;32m    620\u001b[0m         \u001b[0mwords\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mprocess_text\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtext\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 621\u001b[1;33m         \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate_from_frequencies\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mwords\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    622\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    623\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_frequencies\u001b[1;34m(self, frequencies, max_font_size)\u001b[0m\n\u001b[0;32m    451\u001b[0m                 \u001b[0mfont_size\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mheight\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    452\u001b[0m             \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 453\u001b[1;33m                 self.generate_from_frequencies(dict(frequencies[:2]),\n\u001b[0m\u001b[0;32m    454\u001b[0m                                                max_font_size=self.height)\n\u001b[0;32m    455\u001b[0m                 \u001b[1;31m# find font sizes\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_frequencies\u001b[1;34m(self, frequencies, max_font_size)\u001b[0m\n\u001b[0;32m    506\u001b[0m                     font, orientation=orientation)\n\u001b[0;32m    507\u001b[0m                 \u001b[1;31m# get size of resulting text\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 508\u001b[1;33m                 \u001b[0mbox_size\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mdraw\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtextbbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mword\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mfont\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtransposed_font\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0manchor\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m\"lt\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    509\u001b[0m                 \u001b[1;31m# find possible places using integral image:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    510\u001b[0m                 result = occupancy.sample_position(box_size[3] + self.margin,\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\PIL\\ImageDraw.py\u001b[0m in \u001b[0;36mtextbbox\u001b[1;34m(self, xy, text, font, anchor, spacing, align, direction, features, language, stroke_width, embedded_color)\u001b[0m\n\u001b[0;32m    649\u001b[0m                 \u001b[0mstroke_fill\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mstroke_fill\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    650\u001b[0m                 \u001b[0membedded_color\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0membedded_color\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 651\u001b[1;33m             )\n\u001b[0m\u001b[0;32m    652\u001b[0m             \u001b[0mtop\u001b[0m \u001b[1;33m+=\u001b[0m \u001b[0mline_spacing\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    653\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mValueError\u001b[0m: Only supported for TrueType fonts"
     ]
    }
   ],
   "source": [
    "\n",
    "from wordcloud import WordCloud\n",
    "\n",
    "\n",
    "total_text = \" \".join(abstract for abstract in data['Abstract'])\n",
    "\n",
    "word_cloud = WordCloud().generate(total_text)\n",
    "\n",
    "plt.imshow(word_cloud, interpolation='bilinear')\n",
    "plt.axis(\"off\")\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "And here like we see in the barplot the main themes of the corpus center around patient, treatment, efficacy, clinical trial, result which is what we would expect from data which is meant to center around clinical trial results and mechanisms of actions of drug test. Let's see if we can already get a clue about the most frequent topics by generating a wordcloud from the titles."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "Only supported for TrueType fonts",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[1;32mC:\\Users\\ARIESE~1\\AppData\\Local\\Temp/ipykernel_21816/2516889012.py\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[0mtotal_title\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;34m\" \"\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtitle\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mtitle\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mcleaned_titles\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      4\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 5\u001b[1;33m \u001b[0mword_cloud\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mWordCloud\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtotal_title\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m      6\u001b[0m \u001b[0mplt\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mimshow\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mword_cloud\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0minterpolation\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m\"bilinear\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      7\u001b[0m \u001b[0mplt\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0maxis\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m\"off\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate\u001b[1;34m(self, text)\u001b[0m\n\u001b[0;32m    637\u001b[0m         \u001b[0mself\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    638\u001b[0m         \"\"\"\n\u001b[1;32m--> 639\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate_from_text\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtext\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    640\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    641\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m_check_generated\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_text\u001b[1;34m(self, text)\u001b[0m\n\u001b[0;32m    619\u001b[0m         \"\"\"\n\u001b[0;32m    620\u001b[0m         \u001b[0mwords\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mprocess_text\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtext\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 621\u001b[1;33m         \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mgenerate_from_frequencies\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mwords\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    622\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    623\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_frequencies\u001b[1;34m(self, frequencies, max_font_size)\u001b[0m\n\u001b[0;32m    451\u001b[0m                 \u001b[0mfont_size\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mheight\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    452\u001b[0m             \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 453\u001b[1;33m                 self.generate_from_frequencies(dict(frequencies[:2]),\n\u001b[0m\u001b[0;32m    454\u001b[0m                                                max_font_size=self.height)\n\u001b[0;32m    455\u001b[0m                 \u001b[1;31m# find font sizes\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\wordcloud\\wordcloud.py\u001b[0m in \u001b[0;36mgenerate_from_frequencies\u001b[1;34m(self, frequencies, max_font_size)\u001b[0m\n\u001b[0;32m    506\u001b[0m                     font, orientation=orientation)\n\u001b[0;32m    507\u001b[0m                 \u001b[1;31m# get size of resulting text\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 508\u001b[1;33m                 \u001b[0mbox_size\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mdraw\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtextbbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mword\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mfont\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtransposed_font\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0manchor\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m\"lt\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    509\u001b[0m                 \u001b[1;31m# find possible places using integral image:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    510\u001b[0m                 result = occupancy.sample_position(box_size[3] + self.margin,\n",
      "\u001b[1;32m~\\AppData\\Local\\Packages\\PythonSoftwareFoundation.Python.3.9_qbz5n2kfra8p0\\LocalCache\\local-packages\\Python39\\site-packages\\PIL\\ImageDraw.py\u001b[0m in \u001b[0;36mtextbbox\u001b[1;34m(self, xy, text, font, anchor, spacing, align, direction, features, language, stroke_width, embedded_color)\u001b[0m\n\u001b[0;32m    649\u001b[0m                 \u001b[0mstroke_fill\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mstroke_fill\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    650\u001b[0m                 \u001b[0membedded_color\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0membedded_color\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 651\u001b[1;33m             )\n\u001b[0m\u001b[0;32m    652\u001b[0m             \u001b[0mtop\u001b[0m \u001b[1;33m+=\u001b[0m \u001b[0mline_spacing\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    653\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mValueError\u001b[0m: Only supported for TrueType fonts"
     ]
    }
   ],
   "source": [
    "cleaned_titles = data['Title'].apply(clean_text)\n",
    "\n",
    "total_title = \" \".join(title for title in cleaned_titles)\n",
    "\n",
    "word_cloud = WordCloud().generate(total_title)\n",
    "plt.imshow(word_cloud, interpolation=\"bilinear\")\n",
    "plt.axis(\"off\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "So also here to main themes are reviews and clinical trials of certain treatment based on EBM and MOA."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<a name='1'></a>\n",
    "## So after the cleaning function is used several things are altered or removed.\n",
    "1. The text is converted to lowercase, HTML tags are removed.\n",
    "3. Contractions like \"n't\" or \"'ll\" are expanded to their full form.<br>\n",
    "5. Possessive forms like \"'s\" are removed.\n",
    "6. The symbol \"&\" is replaced with the word \"and\".\n",
    "8. Repeated periods are reduced to a single period.\n",
    "10. Stop words are removed, and the remaining words are lemmatized.<br>\n",
    "In summary the preprocessing code performs various text cleaning operations, including the removal of HTML tags, contraction expansion, and lemmatization. \n",
    "Now you can observe that the highest frequency word is no longer a stopword and it's frequency is only 20% of the original most frequent word \"of\". Now one could argue that removing stopwords is a good thing since most of them don't carry much context, which is true most of the times  and combined with lemmatization it would make the corpus and each document smaller leading to the possibility of more context to the LLM in the future. But consider the following example and chain of thought where I will reason that some stop words do carry context and in the context of this retrieval augmented generation and removing certain stopwords could invert the conclusion of a research paper."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Intravenous pentamidine is used for prophylaxis against Pneumocystis jirovecii pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by CYP2C19, which is vulnerable to pharmacogenetic variation. This retrospective study evaluated allogeneic hematopoietic stem cell transplant patients who received intravenous pentamidine as P. jirovecii pneumonia prophylaxis. The primary objective was the association between CYP2C19 phenotype and discontinuation of pentamidine due to drug-related side effects based on univariate logistic regression (NÂ =Â 81). Ten patients (12.3%) discontinued pentamidine because of side effects. There was no difference in discontinuation between phenotype groups (pÂ =Â 0.18) or discontinuation due to side effects (pÂ =Â 0.76). Overall, no association was seen between phenotypes and pentamidine-related side effects (pÂ =Â 0.475). Drug discontinuation rates and P. jirovecii pneumonia infection rates were low.\n",
      "intravenous pentamidine used prophylaxis pneumocystis jirovecii pneumonia, infection seen hematopoietic stem cell transplant recipients. pentamidine partially metabolized cyp2c19, vulnerable pharmacogenetic variation. retrospective study evaluated allogeneic hematopoietic stem cell transplant patient received intravenous pentamidine p. jirovecii pneumonia prophylaxis. primary objective association cyp2c19 phenotype discontinuation pentamidine due drug-related side effect based univariate logistic regression (n = 81). ten patient (12.3%) discontinued pentamidine side effects. difference discontinuation phenotype group (p = 0.18) discontinuation due side effect (p = 0.76). overall, association seen phenotype pentamidine-related side effect (p = 0.475). drug discontinuation rate p. jirovecii pneumonia infection rate low.\n"
     ]
    }
   ],
   "source": [
    "print(data['Abstract'].iloc[4])\n",
    "print(cleaned_data.iloc[4])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now the first abstract is not cleaned and the second abstract is cleaned with stopwords removed and the words lemmatized. First the conclusion of a paper often contain the key findings of the research with a summary a context change here resulting from stopword removal could prove catastrophic in drug justification based on EBM where we look a results of studies to find a solution or a justification to our own problem. Now let's look at the conclusion of the original abstract where it is stated that Overall, no association was seen between phenotypes and pentamidine-related side effects (p = 0.475) and the cleaned_abstract which concludes overall, association seen phenotype pentamidine-related side effect (p = 0.475). This cleaned abstracts conclusion is the complete opposite which says there is association in side effects and giving this text as context for the LLM could result in a wrong justification of a fact based on incorrect information due to the removal of stopwords. Perhaps a more domain specific list of stopwords could be used where these kinds of \"important stopwords\" which don't lose context when removed are present. BUT this is only for the abstract giving context to the LLM what if I still clean the text but specifically for the embedding, even though the conclusion might be off the embedding would still match a high similarity to the fact or question needing justification and then I would retrieve the k most similar uncleaned abstracts or chuncks for the full context. For example consider the following fact needing justification or correction: pentamidine is discontinued due to drug-related side effects from stemming from the CYP2C19 phenotype would still match high similarity to the cleaned and embedded abstract with the wrong conclusion but the conclusion is irrelevant at this stage we just want to match k most similar documents for context and removing stopwords for efficient embedding and maintaining context while removing noise in the embedding could prove beneficial. Then when the k most similar abstract embeddings are matched to the question their original abstracts or chunks thereof with the correct information would would be used as context. so in summary since the primary goal in the initial step is to maximize the similarity matching for retrieval purposes, then cleaning the text by removing stopwords and irrelevant details could prove beneficial."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Proposed structure:\n",
    "\n",
    "Chunking: First, perform chunking on the original uncleaned abstracts. This will divide each abstract into smaller sections as not to fill up the entire context window while preserving the original context. Each chunk will be stored  with an id, which can be useful for tracking.\n",
    "\n",
    "Cleaning: After chunking the data, I would start with cleaning, for example removing stopwords. Cleaning is only for the text embeddings to remove the noise of stopwords from the embedding context to be better matched to a fact.\n",
    "\n",
    "Embedding: Once you have cleaned the data, generate embeddings for each cleaned chunk. These will be used to calculate similarities and retrieve the most relevant original chunks when passed to the LLM for context.\n",
    "\n",
    "tuple Structure: To maintain the link between cleaned chunks and their corresponding uncleaned versions, create a structured data format, such as a tuple. This format will take the shape of the chunk ID and the embedding of the cleaned chunk. This structure might enable me to match the cleaned chunks with questions and retrieve the uncleaned context."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unique words count with stopwords= 100266\n",
      "Unique words count without stopwords and further cleaning= 90317\n"
     ]
    }
   ],
   "source": [
    "unique_words_set = set(\" \".join(data['Abstract']).split())\n",
    "unique_words_count = len(unique_words_set)\n",
    "\n",
    "unique_words_set_cleaned = set(\" \".join(cleaned_data).split())\n",
    "unique_words_count_cleaned = len(unique_words_set_cleaned)\n",
    "print(\"Unique words count with stopwords= \" + str(unique_words_count))\n",
    "print(\"Unique words count without stopwords and further cleaning= \"+ str(unique_words_count_cleaned))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "So we can see cleaning indeed shrinks the corpus and might make word embeddings more concise on their similarity with a fact without the stopwords. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's first what the average sentence and abstract lengths are in our raw abstracts to see how badly we would need chunking for a regular LLM model with 4096 tokens."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average sentence length 22.76748215502177\n",
      "Average abstract 275.5633626097867\n"
     ]
    }
   ],
   "source": [
    "row_count = data.shape[0]\n",
    "total_abstract_length = 0\n",
    "total_sentence_length = 0\n",
    "sentence_count = 0\n",
    "for abstract in data['Abstract']:\n",
    "    sentences = sent_tokenize(abstract)\n",
    "    total_abstract_length += len(abstract.split())\n",
    "    sentence_count += len(sentences)\n",
    "    total_sentence_length += sum(len(sentence.split()) for sentence in sentences)\n",
    "\n",
    "        \n",
    "avg_abstract_length = total_abstract_length / row_count\n",
    "avg_sentence_length = total_sentence_length / sentence_count\n",
    "\n",
    "\n",
    "print(\"Average sentence length \" + str(avg_sentence_length))\n",
    "print(\"Average abstract \"+ str(avg_abstract_length))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x900 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "abstract_lengths = [len(abstract.split()) for abstract in data['Abstract']]\n",
    "\n",
    "sns.histplot(abstract_lengths)\n",
    "plt.title(\"Distribution of abstract lengths\")\n",
    "plt.xlabel(\"Abstract length\")\n",
    "plt.ylabel(\"Count\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Smallest abstract length: 13\n",
      "Largest abstract length: 1901\n"
     ]
    }
   ],
   "source": [
    "abstract_lengths.sort()\n",
    "largest = abstract_lengths[len(abstract_lengths) -1]\n",
    "smallest = abstract_lengths[0]\n",
    "print(\"Smallest abstract length: \" + str(smallest))\n",
    "print(\"Largest abstract length: \" + str(largest))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "So we need some degree of chunking since even though the average abstract length isn't too big there are some outliers and these could fill up our context window coupled with some other abstracts in the same category if found similar. Now let's review if the smaller abstracts contain any relevant information regarding drug efficacies and EBM trials or if they are pretexts of the paper they are discussing with no scientific data such as test and trial results included."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PubMedID</th>\n",
       "      <th>Title</th>\n",
       "      <th>URL</th>\n",
       "      <th>Abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>345</th>\n",
       "      <td>35692074</td>\n",
       "      <td>Bronchial thermoplasty: State of the art.</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/35692074</td>\n",
       "      <td>Since the publication of a sham-controlled, ra...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1371</th>\n",
       "      <td>31880233</td>\n",
       "      <td>Dissociating the Clinical Role and Economic Va...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/31880233</td>\n",
       "      <td>No funding supported the writing of this comme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1642</th>\n",
       "      <td>31017622</td>\n",
       "      <td>Evaluation of Ivermectin vs Permethrin for Tre...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/31017622</td>\n",
       "      <td>Is the use of ivermectin in patients infested ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1774</th>\n",
       "      <td>30561146</td>\n",
       "      <td>Effectiveness of pharmaceutical interventions ...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/30561146</td>\n",
       "      <td>Meibomian gland dysfunction is one of the most...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1914</th>\n",
       "      <td>30120774</td>\n",
       "      <td>Getting to Long-Term Effectiveness and Safety ...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/30120774</td>\n",
       "      <td>Attention-deficit hyperactivity disorder (ADHD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5706</th>\n",
       "      <td>10961441</td>\n",
       "      <td>Clinical experience with Cerebrolysin.</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/10961441</td>\n",
       "      <td>Cerebrolysin is a peptidergic drug which displ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5721</th>\n",
       "      <td>10744306</td>\n",
       "      <td>Clinical measurement, statistical analysis, an...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/10744306</td>\n",
       "      <td>The National Acute Spinal Cord Injury Studies ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5776</th>\n",
       "      <td>9594927</td>\n",
       "      <td>Lipid altering or antioxidant vitamins for pat...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/9594927</td>\n",
       "      <td>Evidence supports the idea that substantial be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5791</th>\n",
       "      <td>9196574</td>\n",
       "      <td>Interferon beta: the current position.</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/9196574</td>\n",
       "      <td>Treatments that reduce disease activity in mul...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5792</th>\n",
       "      <td>9050136</td>\n",
       "      <td>Other chemotherapy regimens including mitoxant...</td>\n",
       "      <td>https://pubmed.ncbi.nlm.nih.gov/9050136</td>\n",
       "      <td>This article reviews the role of systemic chem...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>154 rows Ã— 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      PubMedID                                              Title  \\\n",
       "345   35692074          Bronchial thermoplasty: State of the art.   \n",
       "1371  31880233  Dissociating the Clinical Role and Economic Va...   \n",
       "1642  31017622  Evaluation of Ivermectin vs Permethrin for Tre...   \n",
       "1774  30561146  Effectiveness of pharmaceutical interventions ...   \n",
       "1914  30120774  Getting to Long-Term Effectiveness and Safety ...   \n",
       "...        ...                                                ...   \n",
       "5706  10961441             Clinical experience with Cerebrolysin.   \n",
       "5721  10744306  Clinical measurement, statistical analysis, an...   \n",
       "5776   9594927  Lipid altering or antioxidant vitamins for pat...   \n",
       "5791   9196574             Interferon beta: the current position.   \n",
       "5792   9050136  Other chemotherapy regimens including mitoxant...   \n",
       "\n",
       "                                           URL  \\\n",
       "345   https://pubmed.ncbi.nlm.nih.gov/35692074   \n",
       "1371  https://pubmed.ncbi.nlm.nih.gov/31880233   \n",
       "1642  https://pubmed.ncbi.nlm.nih.gov/31017622   \n",
       "1774  https://pubmed.ncbi.nlm.nih.gov/30561146   \n",
       "1914  https://pubmed.ncbi.nlm.nih.gov/30120774   \n",
       "...                                        ...   \n",
       "5706  https://pubmed.ncbi.nlm.nih.gov/10961441   \n",
       "5721  https://pubmed.ncbi.nlm.nih.gov/10744306   \n",
       "5776   https://pubmed.ncbi.nlm.nih.gov/9594927   \n",
       "5791   https://pubmed.ncbi.nlm.nih.gov/9196574   \n",
       "5792   https://pubmed.ncbi.nlm.nih.gov/9050136   \n",
       "\n",
       "                                               Abstract  \n",
       "345   Since the publication of a sham-controlled, ra...  \n",
       "1371  No funding supported the writing of this comme...  \n",
       "1642  Is the use of ivermectin in patients infested ...  \n",
       "1774  Meibomian gland dysfunction is one of the most...  \n",
       "1914  Attention-deficit hyperactivity disorder (ADHD...  \n",
       "...                                                 ...  \n",
       "5706  Cerebrolysin is a peptidergic drug which displ...  \n",
       "5721  The National Acute Spinal Cord Injury Studies ...  \n",
       "5776  Evidence supports the idea that substantial be...  \n",
       "5791  Treatments that reduce disease activity in mul...  \n",
       "5792  This article reviews the role of systemic chem...  \n",
       "\n",
       "[154 rows x 4 columns]"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "max_length = 100\n",
    "\n",
    "# Filter the DataFrame\n",
    "short_abstracts = data[data['Abstract'].apply(lambda x: len(x.split())) < max_length]\n",
    "\n",
    "# Display the short abstracts\n",
    "short_abstracts\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Since the publication of a sham-controlled, randomized trial (AIR2) and subsequent marketing approval by the US Food and Drug Administration, we have significantly advanced our understanding of bronchial thermoplasty (BT)'s scientific basis, long-term safety, clinical efficacy and cost-effectiveness. In particular, the last 2â€‰years have witnessed multiple research publications on several of these counts. In this review, we critically appraise our evolving understanding of BT's biologic underpinnings and clinical impact, offer an evidence-based patient workflow guide for the busy pulmonologist and highlight both current challenges as well as potential solutions for the researcher and the clinician.\n",
      "No funding supported the writing of this commentary. The author has nothing to disclose.\n",
      "Is the use of ivermectin in patients infested with scabies associated with improved clinical and safety outcomes compared with permethrin? Both ivermectin and permethrin treatment were associated with high clearance rates. There is low-certainty evidence that ivermectin was associated with slightly lower rates of complete clearance after 1 week compared with permethrin, 5%, cream (relative risk [RR], 0.65; 95% CI, 0.54-0.78). After 2 weeks, there was no difference in efficacy (RR, 0.91; 95% CI, 0.76-1.08; low-certainty evidence), or in the number of participants with adverse events (week 4: RR, 1.30; 95% CI, 0.35-4.83; low-certainty evidence).\n",
      "Meibomian gland dysfunction is one of the most common ocular disorders encountered by ophthalmologists and is the leading cause of evaporative dry eye. The disease causes significant morbidity in the population such that patients seek treatment. Multiple clinical studies on pharmacological and mechanical interventions for the treatment of meibomian gland dysfunction have been evaluated. However, there is limited comparative clinical evidence for the effectiveness of these interventions. This review paper aims to report the clinical evidence for pharmaceutical interventions for meibomian gland dysfunction in order to guide clinicians in the management of the disease.\n",
      "Attention-deficit hyperactivity disorder (ADHD) medication use has dramatically increased in youth worldwide. Recent prevalence data in some European countries show expanded use with one country now matching US usage. Still, substantial geographic differences by country remain regarding the extent to which children receive ADHD medications. These geographic differences by country raise research questions about which country's prevalence data represents appropriate medication use. We urgently need country level studies to contribute to our understanding of an appropriate prevalence of ADHD medication use.\n",
      "Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.\n",
      "Polymyalgia rheumatica is effectively treated with glucocorticoids. However, glucocorticoid treatment can cause numerous and potentially serious side effects. Therefore, lowest effective dose and shortest duration to control disease is aimed for and glucocorticoid-sparing treatments are needed. Nevertheless, development of treatment regimens in PMR has been hampered by the lack of reliable classification criteria and evidence-based outcome measures. In this editorial, we discuss the need for valid classification criteria in PMR, the strengths and limitations of the ACR/EULAR 2012 provisional classification criteria for PMR and the need of validation and possible refining of the criteria.\n",
      "Pharmacological treatment of neuropathic pain is associated with side effects and limited efficacy. Recently, the interest in cannabis-based medicine has led to legalisation of medical cannabis in some countries. The aim of this review is to evaluate the evidence of cannabinoids in neuropathic pain. Seventeen trials were identified; eight reported an analgesic efficacy of cannabis-based medicine, and the remaining trials showed no analgesic efficacy. Conclusions were limited by design of studies and short duration of treatment. Overall, the reduction in pain was minimal.\n",
      "The probability of achieving marketing approval of a novel therapeutic for psychiatric indications is extremely low due largely to the inability to demonstrate durable and reproducible efficacy in phase II trials and beyond. These failures are often attributed to the lack of translation of the underlying neuropharmacology from animal model(s) to the disease population. However, how assured is such a conclusion considering the clinical efficacy path rarely meticulously parallels the preclinical experiment(s) that underwrote it?\n",
      "Adjuvant treatment of renal cell carcinoma with vascular endothelial growth factor inhibitors is feasible and effective with careful patient selection and standard dosing levels.\n",
      "We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.\n",
      "Evidence-based guidelines recommend inhaled long-acting anti-muscarinic agents (LAMAs) as first-line maintenance therapy for symptomatic patients with COPD. Several LAMAs are now available for use either as monotherapy or in combination with other COPD medications, including long-acting Î²2-agonists (LABAs) or inhaled corticosteroids (ICS). The efficacy and long-term safety of these medications have been evaluated in multiple clinical trials and real-life studies. This review evaluates the evidence available on the safety of existing LAMAs alone or in combination with LABAs and ICS in patients with COPD.\n",
      "The management of atherosclerotic renal artery stenosis (ARAS) in patients with hypertension has been the topic of great controversy. Major contemporary clinical trials such as the Cardiovascular Outcomes for Renal Artery lesions (CORAL) and Angioplasty and Stenting for Renal Atherosclerotic lesions (ASTRAL) have failed to show significant benefit of revascularization over medical management in controlling blood pressure and preserving renal function. We present here the implications and limitations of these trials and formulate recommendations for management of ARAS.\n",
      "Osteoporosis is defined as bone mineral density. A PubMed literature review was performed to review preclinical and clinical evidence for the use of teriparatide in osteoporotic patients undergoing spine fusion surgery. Preclinical studies in animal models show that teriparatide increases spinal fusion rates. Early clinical studies show that teriparatide both increases spinal fusion rates and decreases hardware loosening in the setting of postmenopausal osteoporosis. Ongoing additional trials will help formulate preoperative screening recommendations, determine the optimal duration of preoperative and postoperative teriparatide treatment, and investigate its utility in men.\n",
      "The year 2014 was a turning point for the field of renal denervation (RDN) and its potential use to treat resistant hypertension. Tremendous enthusiasm shifted to sober reflection on the efficacy of a technology once touted as the cure to resistant hypertension. The following review highlights 2 major questions: First, does catheter-based RDN lower blood pressure and, second, will RDN using catheter-directed therapy for the treatment of resistant hypertension ever become more than an investigational technology.\n",
      "Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.\n",
      "Currently available data indicate superior therapeutic effects of combination treatment for Alzheimer dementia with memantine and acetylcholine esterase inhibitors in certain clinical contexts. Out of five randomized, placebo-controlled, double-blind trials two showed superior therapeutic effects in comparison to monotherapy with acetylcholinesterase inhibitors regarding various domains. Recently published meta-analyses and cost-benefit analyses also showed positive results. Recently published German guidelines for dementia treatment also take these new data into account and recommend combination treatment in patients with severe dementia on stable donepezil medication. This article gives an overview of current evidence for combination therapy.\n",
      "Randomized controlled trials with aÂ variety of drugs have been performed for approximately 20Â years in order to support functional restitution of motor deficits after a stroke. Nowadays, serotonin reuptake inhibitors show the highest level of evidence due to the largest number of positive studies and Lâ€‘dopa also seems to be effective; however, much fewer studies have been conducted. In the majority of trials amphetamines provided no additional benefits and Dâ€‘cycloserine cannot be recommended either. Future therapeutic approaches, e.g. anti-nogo antibodies and cell therapy are presented.\n",
      "Biologic therapies for psoriasis are associated with loss of response over time. Immunogenicity, suboptimal dosing, low serum drug levels, and intermittent or episodic therapy have been documented as explanations for this phenomenon. Use of an immunomodulatory agent can reduce the risk of immunogenicity and improve clinical response.\n",
      "Acne and rosacea are common inflammatory processes historically classified in the same disease category, but evolving understanding of their disparate pathophysiology and exacerbating factors have generated an enormous armamentarium of therapeutic possibilities. Patients seek over-the-counter therapies first when managing cutaneous disease; therefore, this review defines ingredients considered to be effective over-the-counter acne and rosacea products, their mechanisms, and safe formulations, including botanical components, oral supplements, and other anecdotal options in this vast skin care domain.\n",
      "Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.\n",
      "Administration of antenatal corticosteroids has been standard of care for women between 24 and 34 weeks of gestation who are at risk for preterm delivery for more than 20 years longer in other parts of the world. Although the benefit of steroids in this population has been confirmed, there remain many questions including the frequency of dosing and whether it is possible to expand the gestational age criteria to women likely to deliver before 24 weeks or after 34 weeks. The MFMU Network has played a major role in answering some of these questions.\n",
      "Yes. Injected corticosteroids reduce symptoms of carpal tunnel syndrome (CTS) more effectively than placebo or systemic steroids, but no better than anti-inflammatory medication and splinting, from one to 12 weeks after therapy.\n",
      "Renal denervation has a chequered history. Dramatic reductions in blood pressure after denervation of the renal arteries were observed in early trials, but later trials in which denervation was tested against a sham procedure produced neutral results. Although a sound pathophysiological basis exists for interruption of the renal sympathetic nervous system as a treatment for hypertension, trial data to date are insufficient to support renal denervation as an established clinical therapy. In this Perspectives article, we summarize the currently available trial data, device development, and trials in progress, and provide recommendations for future trial design.\n",
      "Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.\n",
      "A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. NCT00405275 , registered 29 November 2006.\n",
      "We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.\n",
      "Intra-articular injections with glucocorticoids are standard procedures according to therapy guidelines in many rheumatic conditions. There is increasing evidence from clinical trials on the treatment of rheumatoid arthritis that more patients will attain the target of remission using a combination of systemic medication and intra-articular injections with glucocorticoids compared to systemic medication alone. Intra-articular injections with glucocorticoids play an important role in the therapeutic management of pediatric rheumatic diseases. In many countries competency in performing intra-articular injections is among the important skills necessary for certification as a specialist in rheumatology.\n",
      "The IMPROVE-IT study has demonstrated a significant reduction of LDL-C when ezetimibe was given in addition to statins. Although the number of strokes and MI was reduced after 7 to 10 years of this treatment, mortality was unaffected, however. Additive ezetimibe treatment can be recommended only, if a better or longer life has been proved - which is not the case.\n",
      "An evidence-based systematic review of yin yang huo (Epimedium spp.) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.\n",
      "Magnesium plays a key role in many cellular functions and there is growing interest in its role in perioperative medicine. While experimental studies provided promising results for several disease states, clinical trials mainly gave conflicting results. This review article summarizes current knowledge on the homeostasis of magnesium as well as on its proposed indications and recommendations in the clinical setting.\n",
      "This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.\n",
      "Use of intravenous furosemide rather than oral administration in acute decompensated congestive cardiac failure is universally recommended in international guidelines. We argue that this recommendation is not supported by the existing evidence, and suggest that trials should be performed to determine whether larger doses of oral furosemide should be prescribed prior to an IV switch. This could reduce length of hospital admissions and allow for more patients to be managed in the primary care setting.\n",
      "The authors trace the history of metformin and its clinical use to the present day. Recent insights into its mode of action and latest data from experimental and clinical medicine have unraveled novel properties of metformin, which may be particularly useful in the treatment of conditions other than diabetes. Results of ongoing clinical trials will show whether or not the hypoglycemic effect of metformin will become only one of the many to be employed in clinical practice.\n",
      "In 2009, GRAPPA published their first evidence-based recommendations for the treatment of psoriasis and psoriatic arthritis (PsA). Since then, new information has been published and drugs developed. We summarize evidence for the efficacy of available treatments for peripheral joint involvement in PsA. We performed a systematic review of current literature on the efficacy of different therapies, management, and therapeutic strategies for peripheral arthritis involvement in PsA, in order to provide information for the development of the new GRAPPA treatment recommendations.\n",
      "The treatment of depressive episodes is characterized by a delay in response of antidepressant medications and high rates of therapeutic failure. In recent years several open and five controlled trials have demonstrated the antidepressant efficacy of ketamine for major depression. In addition a recent study established the utility of nasal ketamine which may render the necessity of intravenous administration obsolete. The current state of evidence is reviewed and discussed.\n",
      "Urea has been recently proposed for the management of hyponatremia linked to the syndrome of inappropriate secretion of ADH (SIADH). The objective of the study was to review the levels of evidence for treatment of hyponatremia associated with SIADH with urea. We performed a: systematic review of experimental trials and grading according to SIGN. No clinical trials were found. The 6 studies analysed had methodological limitations and were prone to biases. In conclusion, there is no evidence to support the efficacy of urea for the treatment of hyponatremia following SIADH.\n",
      "Intravenous salbutamol is commonly used to treat children with severe asthma unresponsive to inhaled Î²2-agonist therapy. However, in this setting, there is little clinical trial data demonstrating its effectiveness. Additionally, there are significant concerns that intravenous salbutamol-dosing recommendations for children with acute asthma are excessive, and unnecessarily raise the potential for adverse reactions, such as lactic acidosis and tachycardia which, by increasing respiratory workload, exacerbate respiratory failure. Here, we review salbutamol clinical pharmacology and toxicology, evidence relating to its use in acute asthma and highlight gaps in the evidence base.\n",
      "Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma. Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.\n",
      "Although current guidelines do not endorse the use of primary androgen deprivation therapy (PADT) as monotherapy for localized prostate cancer, many patients continue to receive this treatment. New outcomes research confirms that there is no clear reason for use of PADT in men with localized prostate cancer.\n",
      "An evidence-based systematic review of goji (Lycium spp.) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.\n",
      "Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.\n",
      "Available data on the effect of various trace elements on iodine metabolism and function of thyroid gland (TG) were systematized in this article. Subsequently, promising possibilities of herbal therapy in treatment and prevention of TG diseases were considered. Systemic analyis of the results of 3 independent open-label clinical studies performed in accordance with requirements of evidence-based medicine that involved herbal medicinal product AlbaÂ® (root extract of white cinquefoil) was carried out. Therapeutic options of AlbaÂ® use in various TG pathologies were presented.\n",
      "The beta-antagonistic agent propranolol is increasingly being used in clinical trials for the prophylaxis and treatment of post-traumatic stress disorder (PTSD). This article discusses the evidence for the effectiveness of propranolol in the prophylaxis and treatment of PTSD and the ethical implications of research on these treatment approaches. The efficacy of a prophylactic or therapeutic use could not be shown during the last decade. Both treatment approaches raise ethical questions that should already be addressed during the clinical trials.\n",
      "Menopausal symptoms management with high-quality plant extracts from Actaea (Cimicifuga. racemosa rootstock is well-established. Efficacy and safety are supported by research and clinical trials since several decades and backed up by official monographs. However, the recent published Cochrane review on black cohosh neglects major evidence for beneficial effects. The authors' negative conclusions are questionable and call for reply and clarification. Our careful reconsideration of all appropriate placebo-controlled clinical studies reveals a standardized mean difference of 0.385 in favor of black cohosh (pâ€‰<â€‰0.0001).\n",
      "Primary immune thrombocytopenia is a potentially life-threatening condition. Approximately two-thirds of adult patients do not have a sustained response to steroids (first-line therapy). For these patients, a number of other treatment options exist, such as rituximab, splenectomy, immunosuppressants, and thrombopoietin receptor agonists, but they are costly and have side effects. Dapsone is an inexpensive drug with a well-established safety profile. Unfortunately, this treatment option has not been explored adequately. This review is aimed at analyzing the currently available evidence for the use of dapsone as second-line or third-line therapy in primary immune thrombocytopenia.\n",
      "Proprotein convertase subtilisin/kexin type 9 (PCSK 9) is a key regulator of cholesterol homeostasis acting via degradation of the low density lipoprotein (LDL) receptor. Loss of function PCSK 9 mutations result in very low LDL cholesterol serum levels and protection from cardiovascular disease whereas gain of function mutations increase serum LDL cholesterol. Based on in vitro and in vivo data antibodies targeting PCSK 9 have now emerged as a novel treatment option in patients with cardiovascular disease. This review briefly summarizes the biochemistry and function of PCSK9 and the results from recent phase II trials.\n",
      "ERBB2 gene amplification occurs in âˆ¼20% of human breast cancers (BC) and is associated with an adverse clinical prognosis, indicating that it may be playing a critical role in disease pathogenesis. Therapeutic strategies targeting pathologic ERBB2 overexpression have revolutionized the diagnosis and treatment of BC. Indeed, humanized anti-ERBB2 antibodies, small molecule ERBB2 kinase inhibitors and ERBB2-targeting antibody-drug conjugates have proven safety and efficacy based upon evidence from randomized phase III clinical trials. Recent progress in targeting ERBB2 alteration will be reviewed, with focus on data that has informed changes in clinical practice for the treatment of BC.\n",
      "This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: van Miert C, Hill R, Jones L. Interventions for restoring patency of occluded central venous catheter lumens. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD007119. DoI: 10.1002/14651858.CD007119.pub2. Further information for this Cochrane review is available in this issue of EBCH in the accompanying Summary article.\n",
      "Pharmacological treatment of atrial fibrillation in the context of heart failure poses numerous challenges. Management decisions are limited by contraindications to several drugs and the paucity of robust clinical trials that provide evidence-based guidance. This review proposes a structured action plan for managing atrial fibrillation coexisting with heart failure that considers published clinical guidelines and integrates recent data derived from substudies of randomized trials, including the atrial fibrillation and congestive heart failure (AF-CHF) trial. Areas of uncertainty, such as target heart rates in atrial fibrillation and upstream therapies, are also discussed.\n",
      "In 2012, results from three studies in interventional cardiology have enhanced our knowledge on the best practices to improve clinical outcomes. These trials were focused on treatment safety as well as efficacy. The optimal therapeutic strategy for patients undergoing percutaneous coronary intervention continues to evolve.\n",
      "This article discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with genetically engineered anti-TNF-Î± immunoglobulin constructs. Arguments why therapeutic decision-making should not rely on clinical outcome alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-Î± drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term therapies with minimal risk of side effects. Large-scale immunopharmacological knowledge of how patients 'handle' TNF-Î± biopharmaceuticals would also help industry develop more effective and safer TNF-Î± inhibitors.\n",
      "In a placebo-controlled trial, the median time to radiologic documentation of cancer worsening or death was extended by about 6 months, although patients experienced many, often serious, adverse effects.\n",
      "Hyperglycemia during admission for acute myocardial infarction (MI) is common and associated with poor outcomes. Prior studies employed two distinct approaches to improve outcomes in patients with acute MI--one focused on glucose control, and the other on provision of glucose, insulin, and potassium. However, despite multiple largescale studies, the benefits of glucose lowering in the setting of acute MI remain unclear. This article reviews data from observational studies and clinical trials and synthesizes this information into practical recommendations based on available evidence.\n",
      "An evidence-based systematic review of vitamin A by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated and reproducible grading rationale. This paper includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.\n",
      "Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokePrevention Regimen for Effectively Avoiding Second Strokes(PRoFESS) Study Group.\n",
      "Improvement of myocardial reperfusion with a greater use of primary percutaneous coronary intervention, adjunctive pharmacological and mechanical therapies have contributed to a spectacular decrease in mortality of patients presenting with ST-elevation myocardial infarction.\n",
      "Individual differences in response to pharmacologic treatment limits the usefulness of mean data obtained from randomized controlled trials. These individual differences exist even in genetically uniform inbred mouse strains. While stratification can be of value in large studies, the individual patient history is the most effective currently available guide for personalized medicine in psychopharmacology.\n",
      "Anemia and iron deficiency are quite prevalent in patients with heart failure (HF) and may overlap. Both anemia and iron deficiency are associated with worse symptoms and adverse clinical outcomes. In the past few years, there has been an enormous interest in the subject of iron deficiency and its management in patients with HF. In this review, the etiology and relevance of iron deficiency, iron metabolism in the setting of HF, studies on iron supplementation in patients with HF and potential cardiovascular effects of subclinical iron overload are discussed.\n",
      "Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. In recent years, bisphosphonates have been used in children for treatment of a growing number of disorders associated primarily with generalized or localized osteoporosis, genetic and acquired metabolic bone diseases, heterotopic calcifications in soft tissues, and for hypercalcemia. In this review, the authors address the role of and experience with bisphosphonate therapy in disorders of childhood.\n",
      "The U.S. Food and Drug Administration applies regulatory flexibility to balance benefits and risks to subjects in cell-therapy clinical trials.\n",
      "ZilverÂ® PTXÂ® (Cook Medical, Bloomington, IN) is a self-expanding nitinol drug-eluting stent with a polymer-free paclitaxel coating on its outer surface. The stent aims to provide improved treatment for patients with symptomatic peripheral arterial disease in the above-the-knee femoropopliteal arteries. On October 13, 2011, the Food and Drug Administration's (FDA) Circulatory System Devices Panel reviewed the Zilver PTX premarket approval application. This summary aims to describe the discussions and recommendations made during the meeting. Based on the Panel's recommendations, it is anticipated that the device will be approved by the FDA.\n",
      "An evidence-based systematic review of vanadium by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.\n",
      "In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously brought up in similar studies-does aprotinin increase the risk of mortality and renal failure after cardiac surgery? Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results. The present review revisits the aprotinin controversy.\n",
      "The past decade has brought important advances in the understanding of rheumatoid arthritis and its management and treatment. New classification criteria for rheumatoid arthritis, better definitions of treatment outcome and remission, and the introduction of biologic response-modifying drugs designed to inhibit the inflammatory process have greatly altered the approach to managing this disease. More aggressive management of rheumatoid arthritis early after diagnosis and throughout the course of the disease has resulted in improvement in patient functioning and quality of life, reduction in comorbid conditions, and enhanced survival.\n",
      "Ustekinumab, which is approved for the treatment of moderate to severe psoriasis, has been shown in phase II clinical trials to be efficacious in controlling the signs and symptoms of psoriatic arthritis. Ustekinumab appears to be well tolerated, but its longterm safety profile is not yet known.\n",
      "The management of advanced genitourinary malignancies has undergone a major transformation with the advent of novel drugs and targeted therapies in recent years. Assessment of the treatment risks and benefits is required for each patient and therefore better knowledge of the different clinical and molecular aspects of these diseases is warranted. The results of further studies and biomarker validations are expected to provide more treatment options and improve outcomes in the future management of genitourinary malignancies.\n",
      "Limitations of commonly used anticoagulants, unfractionated heparin, low-molecular-weight heparin, and oral vitamin K antagonists have prompted the development of alternative therapies. Direct thrombin inhibitors are a new class of anticoagulants that bind directly to thrombin and inhibit its interaction with substrates. In this Review, we critically examine the evidence from randomized controlled trials for the efficacy and safety of the parenteral direct thrombin inhibitors bivalirudin and argatroban, and the novel oral direct thrombin inhibitor dabigatran etexilate, in cardiovascular and thrombotic disease.\n",
      "This article reviews evidence-based pharmacotherapy for children and adolescents with depression. Several randomized controlled trials (RCTs) support the use of fluoxetine for the treatment of childhood and adolescent depression as well as escitalopram in the treatment of adolescent depression. To date, one RCT has demonstrated the effectiveness of sertraline or citalopram for the treatment of major depressive disorder in youth. Only a small number of RCTs for depression have included children, and none of these trials were adequately powered to detect differences in the efficacy of medication between children and adolescents.\n",
      "The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.\n",
      "Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa - rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF.\n",
      "Vitamin D has garnered much research and debate about supplementation in recent years, not only as it pertains to patients with kidney disease but also to those in the general population. This review discusses observational and available clinical trial evidence about the effects of both calcitriol and vitamin D analogs (active) and ergocalciferol and cholecalciferol (nutritional) vitamin D in patients with CKD and ESRD.\n",
      "Antithrombotic therapy and revascularization are critical factors in managing patients presenting with acute coronary syndromes and are described in multiple guidelines documents. In addition to preventing intravascular thrombosis, they increase the risk of bleeding, which has been implicated as a risk factor in short- and long-term mortality. Randomized controlled trials provide useful aggregate information comparing the risks and benefits of various therapies. In this paper, we will use a case-based format to discuss optimal individualized antithrombotic treatments.\n",
      "Persons with alpha1-antitrypsin (A1AT) deficiency and chronic obstructive pulmonary disease (COPD) have been tested for the clinical value of regular intravenous infusion with A1AT in two small double-blind randomised controlled trials. The trials found a statistical significant reduction in the decrease of lung density measured by computed tomographies, but found no clinical nor statistical significant difference in respiratory symptoms, quality of life, lung function, use of medication, exacerbations, respiratory infections or survival. Based on the present evidence A1AT substitution therapy cannot be recommended.\n",
      "The paper reflects contemporary views of the role of antiplatelet therapy in secondary prevention of cardiovascular diseases in patients with coronary heart disease and ischemic stroke. On the basis of evidence based medicine analytical characteristics of all antiplatelet drugs subjected to clinical trials in the world are presented. Advantages and imperfectness of each agent both as monotherapy and used in combinations are demonstrated. Main principles of selection of antiplatelet drugs in patients after ischemic stroke, myocardial infarction, or in stable manifestations of coronary atherosclerosis are also given.\n",
      "Intra-articular hyaluronic acid preparations have been available for the treatment of osteoarthritis of the knee for over 15 years. Their use has been limited by cost, difficulties of administration and conflicting evidence of efficacy. Difficulties in conducting adequate clinical trials have resulted in the appearance of multiple meta-analyses whose findings are not congruent. The appearance of a single injection agent and a better understanding of the mechanisms by which this intervention is effective may help to solve this ongoing problem in healthcare research.\n",
      "Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.\n",
      "Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.\n",
      "In numerous situations stroke physicians face a lack of evidence during their daily practice. In this report the authors address some of the difficult treatment decisions encountered in acute therapy and secondary prevention. Examples include off-label thrombolysis and prevention in high-risk situations. The available data from trials and registries are discussed, and personal views and recommendations are expressed.\n",
      "Contrary to the decline in the prevalence of several risk factors such as hypertension, hypercholesterolemia and smoking, diabetes is an expanding health burden in the western world. Because of the proatherosclerotic, proinflammatory, and prothrombotic states associated with diabetes, diabetic patients with acute coronary syndromes (ACS) are at high risk of subsequent cardiovascular events. However, they derive greater benefit from aggressive platelet inhibition and an early invasive strategy than non-diabetic individuals. Despite the documented efficacy, diabetic patients with ACS receive evidence-based treatments less frequently than non-diabetic individuals.\n",
      "Over the past 5â€“10 years, the positive effects of erythropoietin on myocardial infarction have been reported in several experimental, animal models. However, the results of the REVEAL study call into question the beneficial effects of erythropoietin in humans presenting with myocardial infarction.\n",
      "The population is aging, the prevalence of heart failure increases with age, and on average women live longer than men. There is evidence for sex-specific effects of individual, guideline-recommended drugs used for treatment of chronic heart failure. Women are underrepresented in most clinical trials and only a minority of drug applications to regulatory authorities have included sex analyses. The present review focuses on the potential female survival benefit in heart failure, the influence of sex on medical treatment in a broader sense, and the potential benefit to be derived from guideline recommended treatment and common adjunctive heart failure medication.\n",
      "Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.\n",
      "The ACCORD study investigators have published the results of an extended follow-up of the trial, focused on patients with type 2 diabetes mellitus who had been initially assigned to different intensities of glucose control. These data add to existing knowledge on the benefits of glycemic control in this patient population.\n",
      "There is a high prevalence of sleep disorders in children and an apparent increasing need for pharmacologic management. However, because of the paucity of data available with regards to dosing, efficacy, tolerability, and safety profiles of medications as well as a lack of adequate well-designed clinical trials, medications are currently not approved for the pediatric population by the US Food and Drug Administration. There are no pharmacologic guidelines for the specific sleep disorders or the different pediatric age ranges. Additional research is needed for evidence-based pediatric sleep pharmacotherapy. This article reviews pediatric sleep disorders and the pharmacologic therapeutic options.\n",
      "The recent Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial reported that nateglinide, a non-sulfonylurea insulin secretagogue, failed to prevent progression from impaired glucose tolerance to diabetes. In order to determine the beneficial effect of insulin secretagogues as a class in diabetes prevention, we performed a literature search for randomized controlled studies and review articles on diabetes prevention and use of sulfonylureas, nateglinide, and meglitinide in PubMed and Ovid Medline since 1950. Three studies were identified with none of them reporting success in preventing diabetes, indicating that insulin secretagogues should not be recommended for diabetes prevention.\n",
      "Time window for thrombolysis in acute ischemic stroke can be based on chronological or physiological (imaging) data. Both of these approaches have their unique strengths and weaknesses. The concept of chronological-based thrombolysis is supported by several randomized clinical trials whereas imaging-based thrombolysis has not been validated entirely by randomized trials. Therefore, careful evaluation of strategies using image-based identification of patients who might benefit from thrombolysis is needed. Patients undergoing thrombolysis on delayed arrival appear to be the most logical group in whom image-based strategies should be evaluated.\n",
      "The prognosis of patients with undifferentiated arthritis (UA) may vary from self-limited to severe destructive rheumatoid arthritis (RA). Based on the chance that these patients will develop RA and based on the safety profile of a course of methotrexate for 30-90 days, many clinicians consider using methotrexate in this patient category using the \"n of 1\" trial principle. During the last few years, more data on interventions in UA have become available that provide guidance in the prescription of drugs to UA patients.\n",
      "Whether thiazolidinediones should be used to treat patients with type 2 diabetes mellitus is controversial, as studies on the cardiovascular effects of these drugs have produced conflicting results. A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis.\n",
      "Apixaban is an orally active, selective, direct-acting, reversible inhibitor of factor Xa that is under evaluation for the management of acute coronary syndromes (ACS). This article critically reviews the rationale and evidence for the use of anticoagulants in the long-term management of ACS, preliminary data for apixaban from the phase 2 apixaban for prevention of acute ischemic and safety events (APPRAISE) trial, and the potential future role of apixaban for this indication.\n",
      "The treatment of nonarteritic anterior optic neuropathy remains very limited and disappointing. Recent publications have suggested that oral steroids as well as intravitreal injections of steroids might be helpful to accelerate resolution of disc edema and improve visual outcome. However, the use of steroids to treat acute NAION remains largely debated.\n",
      "There are various treatment options for hidradenitis suppurativa (HS), a recurrent and suppurative disease, but none is wholly satisfactory or effective. There have been many reports on the efficacy of biologic drugs for the treatment of HS; this article is an in-depth review of the published evidence on this topic. Because the current evidence is limited, randomized, double-blinded, placebo-controlled trials are needed to better elucidate the future of these drugs for the treatment of HS.\n",
      "Drug-eluting stents reduce restenosis, particularly in uncomplicated lesions. Despite limited on-label indications, drug-eluting stents have been universally adopted. However, there have been early sporadic reports of stent thrombosis. This article will review the risk factors for stent thrombosis and will briefly discuss recent trials comparing the safety, efficacy, and mortality for bare-metal and drug-eluting stents.\n",
      "Survival for premature neonates has improved dramatically over the past 20 years; however, there has been minimal improvement in prematurity-associated morbidities. Morbidity rates and assessment of outcomes vary across neonatology intensive care units (NICUs). Here, we address the reasons underlying these differences, note the impact that this center variation has on trial design and interpretation, and highlight the success of the efforts in pediatric oncology to develop standards of care through the conduct of multicenter clinical trials.\n",
      "Medical, percutaneous, and surgical therapies for coronary atherosclerotic disease are developing rapidly, with many recent breakthroughs in metabolic control, improvements in catheter and stent engineering, and advances in surgical technique. Treatment guidelines are still in their infancy and do not take into account several of these recent innovations. Consequently, determining the most appropriate treatment for many patients remains challenging. In this review, we examine the most recent revascularization guidelines, discuss important new data and trials comparing contemporary stent technology and coronary artery bypass surgery, and conclude with updated revascularization recommendations.\n",
      "Necrotizing vasculitis continues to be a condition where difficult diagnostic and treatment decisions need to be made, with only a few well-done studies as clinical reference and support. New data suggest that both methotrexate and azathioprine may be effective agents for maintaining remission in antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis after remission is achieved with cyclophosphamide-based therapies. In addition, Behcet's syndrome appears to be more common than previously assumed and is likely more common than a combination of ANCA-associated vasculitis (AAV) syndromes.\n",
      "A placebo-verum difference in antidepressant response of at least three points on the Hamilton Depression Rating Scale has been proposed as the threshold for clinical significance in antidepressant trials. Given the considerable clinical and regulatory consequences of such a definition of clinical relevance it deserves a critical discussion. Eight arguments are presented indicating that using this definition as a criterion for assessing the clinical utility of antidepressants in daily practice would risk erroneously discarding treatments with a clear benefit for patients.\n",
      "Recurrent urinary tract infections (UTIs) are common in postmenopausal women. While the pathophysiology is often complex, it is evident that the urogenital atrophy due to the decrease of endogenous oestrogen production is a key factor. Two small randomized controlled studies have proven the efficacy of local (vaginal) oestrogen therapy in the prevention of recurrent UTIs. Conversely, four randomized trials, reviewed in a weighted meta-analysis with pooled data from 2,798 women, have shown the lack of efficacy of systemic oestrogen-progesterone therapy. Local oestrogen therapy is recommended, if the predominant indication is urogenital symptoms.\n",
      "Thromboprophylaxis is underused in patients with cancer, despite the fact that malignancy is a serious risk factor for venous thromboembolism in this population. Major medical guidelines, including those published recently by the American College of Chest Physicians, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network, recommend routine thromboprophylaxis for patients with cancer under certain situations. This review describes current recommendations for primary and secondary prophylaxis in patients with cancer.\n",
      "The reporting of adverse events (AEs) in randomized clinical trials (RCTs) is often lacking in the publication of trials. Part of the problem is the way safety data are reported in RCTs. Reporting of \"time to event,\" use of standardized incidence ratios for comparison to normal population or disease controls, use of \"patient years\" when reporting AE, and adequate sample size and power calculations are some of the problems that need to be addressed and improved in RCTs.\n",
      "The last 20 years have shown an incredible improvement in the treatment of bronchial asthma, largely due to an earlier and more diffuse use of the inhaled glucocorticoids, that represent the pharmacological class of anti-asthma drugs more important to control the disease. Considering its efficacy and safety the current pharmacological treatment of asthma will probably remain unchanged for the next 10 years.\n",
      "Increased levels of vascular endothelial growth factor (VEGF) have been associated with a poor prognosis for patients with breast cancer. In addition to its prognostic role, VEGF is also a validated target in the treatment of this disease. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination with either paclitaxel or docetaxel has prolonged progression-free survival and increased response rates in the first-line treatment of patients with metastatic, HER2-negative breast cancer. In this paper, the clinical trials establishing bevacizumab use for the treatment of breast cancer are reviewed.\n",
      "With the endpoint of osteoporosis treatment thus clarified, currently, the selective estrogen receptor modulator (SERM) raloxifene represents the mainstay of therapy for osteoporosis, together with the antiresorptive agents bisphosphonates. Thus, this review has drawn mainly on the results of the MORE study to explore the efficacy of raloxifene in inhibiting bone metabolism, increasing bone mineral density effects, and preventing bone fractures. Notably, the available evidence for raloxifene suggests that the efficacy of raloxifene in preventing bone fractures has not only to do with bone mineral density but also to do with bone quality.\n",
      "There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.\n",
      "Minor depression, subsyndromal depression and subthreshold depression are frequent conditions in primary care which do not fulfil the criteria of a depressive disorder but are associated with functional disability, impairment of quality of life, and health care use. This paper reviews studies on the clinical evidence of pharmacotherapy, psychotherapy, and interventions to improve primary care. In this regard, whether clinical relevance of antidepressant therapies can be concluded from differences between placebo and active treatment is critically discussed. Due to lacking clinical evidence, aspects of a pragmatic therapeutic approach in those patients are presented.\n",
      "Several randomized trials of catheter-directed thrombolysis versus operative revascularization in patients with acute lower extremity ischemia were performed in the mid-1990 s. Although the outcomes of these trials were not definitive, they did provide insight into potential uses and techniques of catheter-directed thrombolysis and lytic agents. This article reviews the outcomes of these randomized trials and describes advances in thrombolytic techniques and technology, including percutaneous mechanical thrombectomy devices and innovative catheter designs that accelerate lysis and the development of direct-acting lytic agents.\n",
      "For most patients with osteoarthritis of the knee, arthroscopic surgery offers little benefit.\n",
      "Very few randomised controlled trials (RCTs) conducted in intensive care units and using mortality as their primary outcome have shown a beneficial effect of pharmacological intervention on survival. Other types of evidence than the RCT should therefore be considered. Observational studies (clinical epidemiological studies) based on public registers and clinical databases have shown good agreement with the results from RCTs. The populations of Denmark and the remaining Scandinavian countries are well-registered and as such an ideal base for clinical, epidemiological studies supplementing the RCTs.\n",
      "Pneumocystis jirovecii is an opportunistic pathogen causing life-threatening pneumonia in immunosuppressed patients. The number of non-HIV immunosuppressed patients at risk for Pneumocystis pneumonia is rapidly growing. In contrast to HIV patients, there are no guidelines for Pneumocystis prophylaxis in other immunocompromised hosts. A detailed analysis of current literature data allowed us hereby to define the type of immunocompromised patients for whom evidence suggests a benefit for PCP prophylaxis.\n",
      "Active vitamin D3 has been most widely used in Japan for the treatment of osteoporosis. Although it mildly increases bone mineral density, it has little consistent effect on bone metabolic markers, and clinical evidence for its efficacy as a fracture-preventing drug is rather weak. Recent reports suggest that (active) vitamin D3 may prevent fracture incidence not only by promoting intestinal calcium absorption but also by improving neuromuscular function to reduce the number of falls.\n",
      "Phase III clinical trials help define standard therapies by comparing the outcomes of a new (experimental) treatment arm to the best established (control) arm. Superior outcomes should only be defined in measures of patient benefit. Two recent trials for upfront therapy of patients with multiple myeloma (ECOG E1A00 and E4A03) failed to conform to traditional Phase III trial design. Consequently they failed to provide any useful scientific data.\n",
      "By the end of 2006, compared with 28% coverage for adults, only 15% of children with HIV that needed antiretroviral treatment were receiving it. Major challenges in delivering treatment include the lack of paediatric antiretrovirals that can be dosed in small children and limited studies examining safety and efficacy for existing antiretroviral formulations. The high costs of treatment have been reduced through the use of generic, fixed-dose combination drugs. Evidence-based strategies for managing resistance and the scale-up of pharmacological trials for children in low- and middle-income countries are crucial to the success and future development of paediatric antiretrovirals.\n",
      "Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies. Recent evidence-based guidelines recommend the once weekly administration of epoetin beta. This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer. The once-weekly administration regimen is convenient for the physician and patient alike. Methods to further optimize this treatment are discussed.\n",
      "This systematic review assesses the effectiveness of antipsychotic medication for improving core psychopathology and behavioral symptoms of anorexia nervosa. The Cochrane Depression, Anxiety and Neurosis Group Trials Register, reference lists of retrieved studies and conference abstracts were searched. Four randomized controlled trials comparing typical or atypical antipsychotic medication to other interventions were included. Clinical heterogeneity precluded meta-analysis. Overall, there is insufficient evidence to either support or refute the use of antipsychotic medication in anorexia nervosa. Further trials may be justified but should be designed with a clear theoretical framework to guide use of antipsychotic medication.\n",
      "To examine long-term outcomes with primary care office-based buprenorphine/naloxone treatment, we followed 53 opioid-dependent patients who had already demonstrated six months of documented clinical stability for 2-5 years. Primary outcomes were retention, illicit drug use, dose, satisfaction, serum transaminases, and adverse events. Thirty-eight percent of enrolled subjects were retained for two years. Ninety-one percent of urine samples had no evidence of opioid use, and patient satisfaction was high. Serum transaminases remained stable from baseline. No serious adverse events related to treatment occurred. We conclude that select opioid-dependent patients exhibit moderate levels of retention in primary care office-based treatment.\n",
      "Psoriatic arthritis is now recognized as a potentially serious and disabling disease. Traditional therapies have not been very effective in controlling signs and symptoms or preventing progression of damage. Based on the pathogenesis of the disease new therapies have been introduced, particularly anti-TNF agents and anti-T cell agents. Several of those have shown excellent responses in clinical variables, health related quality of life and function, and in preventing radiological progression. However, not all patients have responded, and the long-term safety of these drugs remains unknown.\n",
      "Clinical guidelines briefly identify, summarize and evaluate the best evidence and most current data about prevention, diagnosis, prognosis, therapy, risk/benefit and cost-effectiveness. However, the final conclusion about them will be possible only after their use in everyday practice with full freedom of psychiatrists to make changes according their personal judgment about risk and benefit of treatment.\n",
      "Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.\n",
      "Treatment-resistant depression is a serious problem with significant costs in terms of health care dollars and patients' well-being. Vagus nerve stimulation (VNS) is one novel, device-based therapy that may be effective in this population. In this article, we review the evidence to date on the use of VNS in major depression and describe the process of VNS treatment initiation, device implantation, and dosage adjustment and monitoring. It is important for psychiatric nurses to understand the evidence base for and how VNS is used in treatment so they may enhance care of patients with treatment-resistant depression.\n",
      "TNF is a central cytokine in the pathogenesis of rheumatoid arthritis(RA), which induces synovitis as well as joint damage. Etanercept is a recombinant human soluble TNF receptor that binds specifically to TNF receptor, and inhibits TNF receptor-mediated signaling cascade. Recent investigations have revealed successful clinical efficacy of biologics in RA including etanercept. We reviewed here the structure and efficacy of etanercept in RA according to the published evidence.\n",
      "Harpagophytum procumbens, known as devil's claw, has been used traditionally for the treatment of pain, fevers, and dyspepsia. Recently, it has become popular for the treatment of rheumatoid and osteoarthritis. Studies have yet to establish a clear mechanism of action; however, current research is focusing on pro-inflammatory mediators as well as on potential antioxidant characteristics.\n",
      "Two large randomised clinical trials were published in March 2006 that evaluated the effect of natalizumab on the incidence of disease exacerbation in patients with multiple sclerosis (MS). Both trials showed that natalizumab reduces the incidence of MS exacerbations, but it is unclear whether patients ultimately benefited from treatment. It is clear that natalizumab is associated with serious adverse events, such as progressive multifocal leukoencephalopathy. Therefore, the use of natalizumab in patients with MS cannot be considered advisable at this time.\n",
      "Depression in children and adolescents is relatively prevalent and may have serious consequences. Treatment of depressive disorders may be psychotherapeutic or psychopharmacological. A systematic literature search was performed and the evidence for a psychopharmacological treatment of depressive disorders in children and adolescents was described. Emphasis is put on treatment with selective serotonin reuptake inhibitors as these are the best-documented agents in the treatment of depression in children and adolescents.\n",
      "Postherpetic neuralgia is a disorder that occurs frequently in the elderly. As the effect of the treatment of postherpetic neuralgia is often disappointing, studies have focussed on the prevention of this complaint. A commonly used preventive intervention is the administration ofa single epidural injection of a local anaesthetic and a corticosteroid, combined with oral antiviral agents and analgesics. In a large, multicentre, randomised controlled trial, the investigators found that the single injection of a corticosteroid and a local anaesthetic had no added value in the prevention of long-term postherpetic neuralgia.\n",
      "In Denmark, Alzheimer drugs have been registered since 1997. Three cholinesterase inhibitors (donepezil, rivastigmin og galantamin) are approved mild to moderate Alzheimer's disease and one partial NMDA receptor antagonist (memantin) with the indication moderate to severe Alzheimer's disease. The treatment is symptomatic with a parallel shift of the course. The life expectancy does not seem to be altered. There is documented effect on the cholinesterase inhibitors of up to two years and for memantine for 6 months. New disease modifying agents are under clinical development.\n",
      "No patient-oriented evidence supports pneumococcal revaccination of any patient (high-risk or otherwise). Antibody levels may be augmented by revaccination; however, the clinical efficacy of revaccination, even among high-risk patients, is unknown. Revaccination is recommended by the Advisory Committee on Immunization Practices (ACIP) in certain circumstances (strength of recommendation [SOR]: C, expert opinion based on physiology/bench research). Revaccination once appears to be safe, especially if provided 5 years or more after primary vaccination (SOR: B, based upon consistent results of cohort studies and nonrandomized prospective trials).\n",
      "Beta-adrenoceptor blockers and thrombolytic agents are of established value in the pharmacological management of heart failure and ST-elevation myocardial infarction, respectively. However, there is uncertainty as to whether these therapeutic strategies can be safely and effectively adopted in elderly patients with comorbidities, particularly in old-old individuals. This review focuses on these trials and the age-related efficacy and safety of these drugs.\n",
      "Drug-eluting stents are a major breakthrough in cardiology, with the Cypher (Cordis Corporation) and Taxus (Boston Scientific) stents preventing 60-70% of repeat coronary revascularizations, compared with bare metal stents. Both evidence- and risk-based application of drug-eluting stents is expected to create relevant financial and equity problems to most public hospitals, as the cost of drug-eluting stents is over 1000 higher than traditional stents. In the perspective of third-party payers, drug-eluting stents are cost-effective revascularization strategies for a large portion of patients actually undergoing stenting. However, adequate guidelines and reimbursement strategies are still awaited in several countries.\n",
      "Botulinumtoxin A (BTX) is widely used for the treatment of spastic movement disorders in childhood. Safety and local efficacy of BTX are well documented by the experience of many users and verified by several clinical trials. Indications for the use of BTX in children include facilitation of care, better tolerance of ortheses as well as the quantitative and qualitative improvement of motor abilities. This article differentiates clinical indications for which the use of BTX has been proven from those in which effectiveness is only suspected or is yet unclear.\n",
      "Compelling evidence exists to use cinacalcet as a primary therapy for the treatment of secondary HPT in patients requiring dialysis. The benefits of directly lowering PTH in combination with improving calcium-phosphorus homeostasis provide a means to better achieve the K/DOQI bone guidelines. Cinacalcet is usually well tolerated and safe to use, making it possible to treat a wide range of patients with varying levels of disease severity. The ideal course of action for this novel therapy is for nephrology nurses and renal dietitians to use a team approach in the management of secondary HPT.\n",
      "This article discusses current practices in the treatment of bipolar depression. In the absence of more definitive research, the treatment of bipolar depression is guided by clinical experience and expert opinion, and sometimes by marketing and popular trends, as much as it is by hard data. Considering the limitations of current knowledge is an essential component of the scientific practice of psychiatry.\n",
      "The effect of statins to reduce mortality and morbidity in primary and secondary prevention as well as in acute coronary syndrome is well established. Recent data show that pleiotropic effects might also have direct effects on the myocardial cell. However, in chronic heart failure the outcome is inversely related to LDL-plasma concentrations and other pleiotropic effects might impair mitochondrial function. Since there are no safety data on the use of statins in chronic heart failure, a controlled randomized and placebo-controlled trial is urgently needed.\n",
      "Vitamin D, particularly its active form, has been most widely used in Japan for the treatment of osteoporosis. However, clinical evidence for its efficacy as an anti-osteoporotic drug is scarce in terms of fracture prevention. Recent reports suggest that active vitamin D or its analogs may prevent fracture not only through enhancement of intestinal calcium absorption but also by improving bone quality and/or strength independently of bone mass and by improving neuromuscular function to reduce the number of falls.\n",
      "To present an evidence-based practice protocol for oral sucrose administration to minimize neonatal procedural pain. Examination of published research may provide additional modalities to expand an established pediatric pain-management program. The extensive research evaluating oral sucrose supports its inclusion in a pediatric pain-management program. A thorough implementation plan will allow new modalities to be included to optimize procedural pain relief for hospitalized neonates with minimal staff resistance and improved patient outcomes.\n",
      "Ximelagatran (Exanta (TM)) is the first oral agent in a new class of anticoagulants called direct thrombin inhibitors. Most of the available evidence regarding venous thromboembolism is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for ximelagatran and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials.\n",
      "Insomnia and depression are common problems with profound public health consequences. When left untreated, both conditions have high rates of persistence and recurrence. Maintenance treatment for depression is fairly well established, but there is no evidence-based consensus regarding the safety and efficacy of maintenance therapy for insomnia. Consequently, long-term treatment of insomnia is driven primarily by the individual choices of patients and their clinicians. This article compares and contrasts the current state of research in the maintenance therapy of depression and insomnia and highlights gaps in the insomnia literature.\n",
      "Graves' ophthalmopathy (GO) is a challenging disease that poses therapeutic dilemmas for endocrinologists and ophthalmologists. Progress in medical therapy has been slow. Numerous new treatments have been reported to have a beneficial effect. However, current evidence indicates that glucocorticoids (GC) represent the only class of drug therapy which either in isolation or combined with other therapies has an unequivocal role in the routine clinical management of patients with GO. Recent advances include better definition of factors predictive of response to treatment and the formulation of specific GC regimens that combine high efficacy with a low risk of unwanted side-effects.\n",
      "Aspirin, despite being 100-years old, even in the era of evidence-based medicine, remains a valuable analgesic. Results of randomized trials have shown that it is as well effective and safe as other analgesics in relieving mild pain and can be used in the first-line therapy of migraine.\n",
      "Recent experimental studies and clinical trials have revealed that the modulation of either systemic or regional(cardiovascular) renin-angiotensin systems(RAS) is one of the potential targets to prevent the progression of heart failure. Either ACE inhibitor, angiotensin-II receptor blocker or aldosterone antagonist differently block RAS. Many clinical trials told us that each of them improves heart failure and might promise the better prognosis. Now, some experimental studies are encouraging us to test the comparative effects or the effects in combination of them. Here we will summarize the current outcomes from the experimental and clinical studies, and discuss the future direction.\n",
      "Short-term mortality is not reduced with early administration of intravenous magnesium in high-risk patients having an acute myocardial infarction (MI). There is no reason to give intravenous magnesium unless patients have other indications for repletion, such as a low magnesium level or arrhythmia responsive to magnesium therapy.\n",
      "Acetaminophen in doses of 4 g/d did not affect liver function of alcoholic patients in this randomized study. These results do not rule out the possibility of acetaminophen-induced liver failure in alcoholic patients, especially patients with pre-existing liver disease or those who continue to drink. Patient-oriented outcomes (ie, studying chronic acetaminophen use in alcoholics to determine the incidence of developing hepatic failure) ultimately would resolve this controversy. However, these data do cast doubt on the medical myth (based on case reports) that acetaminophen use in alcoholics causes hepatotoxicity.\n",
      "This article is an evidence-based summary of randomized clinical trials published in peer-reviewed journals regarding the efficacy of anticonvulsants for the treatment of neuropathic pain.\n",
      "Over time the recommended duration of antibiotic therapy for patients with erythema migrans has increased. This change in prescribing practice is not evidence-based. The presumptions that post-treatment subjective complaints, which occur in a minority of patients, may be reduced by increasing the duration of initial therapy or ameliorated by a repeat course of parenteral or oral antimicrobials, have not been supported by recent clinical trials. Recommendations on duration of treatment of early Lyme borreliosis deserve critical reappraisal.\n",
      "Controversy concerning the pulmonary artery catheter (PAC) and its use as a bedside clinical tool continues to be a significant bone of contention. In the pursuit of evidence-based medicine, a substantial effort has been made over the last 25 years to demonstrate the benefit or lack thereof of PAC-led therapy, and this endeavor still persists with large, randomized, clinical trials currently in progress both in the United States and in the United Kingdom. This article reviews the core evidence for and against PAC efficacy and safety and considers the most appropriate method for validation of such a device.\n",
      "As exemplified in this discussion of ACLS antiarrhythmic drugs, the evidence-based evaluation process has created a high standard for the acceptance and ranking of therapies for cardiac arrest. This process also has identified critical areas needing further investigation, fostered a healthy sense of discomfort with the adequacy of our present interventions for cardiac arrest, and hopefully will continue to spur the science while sifting the dogma out of CPR.\n",
      "We sketch the development of the effective dose approach which provides a theoretical framework to interpret chemotherapy outcome data. Building on the generalised Skipper model of chemotherapy, a meta-regression method is derived to jointly analyse all chemotherapy comparing randomised clinical trials in a given malignancy in order to explore the slope of the effective dose/outcome relationship and the relative potency of cytostatic drugs. The model is applied to explain why treatment differences in aggressive NHL appear to differ by risk groups in aggressive NHL. A respective meta-subgroup analysis to confirm this interaction hypothesis is proposed.\n",
      "The new clinical guidelines of the US National Cholesterol Education Program (NCEP) were released in May 2001. These guidelines were published as the NCEP's Adult Treatment Panel (ATP) III report. They are derived from an extensive review of the emerging literature so as to provide an evidence-based report. Thanks to recent clinical trials of cholesterol-lowering therapy, it is possible to expand the scope of clinical management for both dietary and drug therapies. This expansion derives from a conclusive demonstration of efficacy, safety, and cost-effectiveness of therapies. This article will review briefly the major features of ATP III.\n",
      "Terms such as efficacy and efficiency of treatment are presently taking on growing importance for medical practice. Two examples are the increasing limitation of cost reimbursement to evidence-based, scientifically proven therapeutic measures and assessment of efficiency in terms of budgeting. We briefly discuss the definition and application of important terms and concepts in this context and ethical and methodological problems involved.\n",
      "The lack of dose adjustment to the individual needs of a patient is a major cause for the substantial difference between the efficacy of therapies established in large trials and the therapeutic results obtained in everyday practice (reduced effectiveness). In addition, these differences affect drug safety and ultimately also costs. Hence strategies to maintain good compliance and to avoid incompatibilities, drug interactions and adverse events should be applied whenever drugs are prescribed. This supplement compiles different techniques and measures which may support health professionals in reaching these goals.\n",
      "Cerebrolysin is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin in Alzheimer's disease. This evidence is based on our clinical experience with Cerebrolysin, stemming from our participation in a double-blind, placebo-controlled clinical trial, a compassionate use programme initiated thereafter, and a PET study. Our data suggests, that Cerebrolysin is a safe and effective treatment for Alzheimer's disease and that repeat treatments may maintain function in patients over the long-term.\n",
      "The National Acute Spinal Cord Injury Studies have been a series of trials assessing the role of pharmacologic agents in the prevention of secondary neuronal damage after acute spinal cord injury. The trials were multicenter randomized, controlled studies. Two trials have demonstrated the efficacy of high-dose methylprednisolone in improving neurologic and functional recovery and have shown a reassuring safety profile. This study responds to a recent commentary on these trials and examines in particular the roles of clinical measurement, statistical analysis, and risk benefit in assembling evidence for or against innovative therapies.\n",
      "Evidence supports the idea that substantial benefits may derive from treatments that increase high density lipoprotein (HDL) cholesterol (HDL-C), apolipoprotein (apo) A-I, HDL2 (or 2b) or the size of HDL particles with, or without, apo A-II. HDL3 appears to be neutral in terms of coronary artery disease risk, and apo A-II appears to be adverse. Because HDL particles serve as antioxidants in vitro, the hypothesis that low HDL-C reflects an antioxidant deficiency state appears tenable. Based on these observations, a three-year angiographic study was proposed and received funding. Enrollment began in January 1995 and was completed in January 1997.\n",
      "Treatments that reduce disease activity in multiple sclerosis are now available, but it is not known how these agents will modify the development of disability in the long term. Published trials of the use of interferon beta failed to detect any clinically relevant reduction in accumulation of disability during the study period. Should patients therefore be prescribed these compounds?\n",
      "This article reviews the role of systemic chemotherapy in the treatment of hormone refractory prostate cancer, with emphasis on the evidence regarding the use of mitoxantrone plus prednisone, suramin, and various investigational regimens. Outcome assessment in this disease has not been uniform; recently evolved measures such as patient-based \"palliative\" endpoints and prostate-specific antigen responses will be discussed.\n"
     ]
    }
   ],
   "source": [
    "for index, row in short_abstracts.iterrows():\n",
    "    print(row['Abstract'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "And while reading through these small abstracts I see that it's a mix. Some abstracts are indeed pretexts but others already provide trial results and medicine efficacies in them so they are useful to keep. And even as pretexts the LLM could use this as a way to explain there have been tests of that drug in your usecase and even though it cannot explain the drugs workings you can find the paper which discusses these results."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "By applying an effective chunking strategy, the similarity search can get as close as possible to capture the essence of the userâ€™s query. If the chunks are too small or too large, it may lead to imprecise search results or missed opportunities to surface relevant content. Now I will first try and make a justification pipeline without cleaning the abstracts before embeddings this will add complexity but results can be compared later. Chunking length will be avg_abstract_length / 2 with an overlap of 50. I believe this will chunk up the documents enough while having overlap to ensure all necessary documents with trial results and MOA methods are also taken with the conclusion regarding a drugs efficacy. Right now I am contemplating the embedding and LLM model to try in my first pipeline. I think for the LLM I will use llama2 since it's the most powerful LLM opensourced, and the for embedding I think will be using the llama-cpp to keep it within the LLama familly. And for vector store I think of using FAISS since it's an efficient local model for storing these vectors and it can do similarity search efficiently\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
